Abstract
Background: Mucopolysaccharidosis type II (MPSII), also known as Hunter syndrome, is an X-linked disorder caused by mutations in the iduronate 2 sulfatase (IDS) gene. This enzyme catalyzes the initial step in the catabolism of heparan sulfate and dermatan sulfate; thus, its deficiency leads to the accumulation of these glycosaminoglycans. MPS II has significant allelic heterogeneity, making the establishment of genotype-phenotype correlations difficult. This study assessed clinical features in combination with deep genotyping of a group of Colombian patients with MPS II and attempted to establish a degree of genotype-phenotype correlation by employing bioinformatic tools.
Methods: Eighteen patients were included in this study, 11% of whom were non-neuronopathic, and the other 89% were neuronopathic. Samples were all analyzed using three molecular methodologies: MLPA, direct exon sequencing, and RFLP analysis.
Results: A total of 13 mutations were identified, 6 of which were novel (c.548_564dup16, c.477insT, c.595_607del12, c. 549_562del13, c.182delC, and a complete deletion of exon 7). The frequency of common mutations (R468Q, Q465X, K347Q, K236N, S71N, R88H, and a conversion phenomenon) was 53.85%. The S71N mutation was frequent among the attenuated phenotype, while private frameshift mutations and rearrangements were seen in patients with severe phenotypes. Molecular docking was performed on the wild-type and mutant IDS proteins, which revealed changes in the enzyme-substrate interaction for the mutant IDS.
Conclusion: The frequency of novel mutations (46.15%) is similar to what has been reported elsewhere. The use of bioinformatic tools showed differences in enzyme-substrate interactions. Studies with larger groups of patients are needed.
Competing interests: None declared
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alves S, Mangas M, Prata MJ et al (2006) Molecular characterization of Portuguese patients with mucopolysaccharidosis type II shows evidence that the IDS gene is prone to splicing mutations. J Inherit Metab Dis 29:743–754
Bondeson ML, Dahl N, Malmgren H et al (1995) Inversion of the IDS gene resulting from recombination with IDS-related sequences is a common cause of the Hunter syndrome. Hum Mol Genet 4:615–621
Brusius-Facchin AC, Schwartz IV, Zimmer C et al (2014) Mucopolysaccharidosis type II: identification of 30 novel mutations among Latin American patients. Mol Genet Metab 111:133–138
Bunge S, Steglich C, Zuther C et al (1993) Iduronate-2-sulfatase gene mutations in 16 patients with mucopolysaccharidosis type II (Hunter syndrome). Hum Mol Genet 2:1871–1875
Bunge S, Rathmann M, Steglich C et al (1998) Homologous nonallelic recombinations between the iduronate-sulfatase gene and pseudogene cause various intragenic deletions and inversions in patients with mucopolysaccharidosis type II. Eur J Hum Genet 6:492–500
Dierks T, Lecca MR, Schlotterhose P, Schmidt B, von Figura K (1999) Sequence determinants directing conversion of cysteine to formylglycine in eukaryotic sulfatases. EMBO J 18:2084–2091
Diez-Roux G, Ballabio A (2005) Sulfatases and human disease. Annu Rev Genomics Hum Genet 6:355–379
Froissart R, Maire I, Millat G et al (1998) Identification of iduronate sulfatase gene alterations in 70 unrelated Hunter patients. Clin Genet 53:362–368
Froissart R, Da Silva IM, Maire I (2007) Mucopolysaccharidosis type II: an update on mutation spectrum. Acta Paediatr Suppl 96:71–77
Galvis J, Gonzalez J, Torrente D, Velasco H, Barreto G (2014) In silico analysis of iduronate 2 sulfatase mutations in Colombian patients with hunter syndrome (MPSII) in: advances in computational biology. Adv Intel Syst Comput 232(2014):205–212
Gómez A, García-Robles R, Suárez-Obando F (2012) Estimación de las frecuencias de las mucopolisacaridosis y análisis de agrupamiento espacial en los departamentos de Cundinamarca y Boyacá. Biomedica 32:602–609
Gucev ZS, Tasic V, Sinigerska I, Kremensky I et al (2011) Hunter syndrome (Mucopolysacharidosis Type II) in Macedonia and Bulgaria. Prilozi 32(2):187–198
Holt J, Poe MD, Escolar ML (2011) Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II. J Pediatr 159(320–326):e322
Isogai K, Sukegawa K, Tomatsu S et al (1998) Mutation analysis in the iduronate-2-sulphatase gene in 43 Japanese patients with mucopolysaccharidosis type II (Hunter disease). J Inherit Metab Dis 21:60–70
Jones SA, Almassy Z, Beck M et al (2009) Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 32:534–543
Kato T, Kato Z, Kuratsubo I et al (2005) Mutational and structural analysis of Japanese patients with mucopolysaccharidosis type II. J Hum Genet 50:395–402
Lagerstedt K, Carlberg BM, Karimi-Nejad R, Kleijer WJ, Bondeson ML (2000) Analysis of a 43.6 kb deletion in a patient with Hunter syndrome (MPSII): identification of a fusion transcript including sequences from the gene W and the IDS gene. Hum Mutat 15:324–331
Lau C, Lam CW (2008) Molecular investigations of a novel iduronate-2-sulfatase mutant in a Chinese patient. Clin Chim Acta 392:8–10
Li P, Thompson JN (1996) Detection of four novel mutations in the iduronate-2-sulphatase gene by single-strand conformation polymorphism analysis of genomic amplicons. J Inher Metab Dis 19(1):93–94
Lin SP, Chang JH, Lee-Chen GJ, Lin DS, Lin HY, Chuang CK (2006) Detection of Hunter syndrome (mucopolysaccharidosis type II) in Taiwanese: biochemical and linkage studies of the iduronate-2-sulfatase gene defects in MPS II patients and carriers. Clin Chim Acta 369:29–34
Lissens W, Seneca S, Liebaers I (1997) Molecular analysis in 23 Hunter disease families. J Inher Metab Dis 20:453–456
Lualdi S, Regis S, Di Rocco M et al (2005) Characterization of iduronate-2-sulfatase gene-pseudogene recombinations in eight patients with Mucopolysaccharidosis type II revealed by a rapid PCR-based method. Hum Mutat 25:491–497
Lualdi S, Tappino B, Di Duca M et al (2010) Enigmatic in vivo iduronate-2-sulfatase (IDS) mutant transcript correction to wild-type in Hunter syndrome. Hum Mutat 31:E1261–E1285
Malm G, Lund AM, Mansson JE, Heiberg A (2008) Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr 97:1577–1581
Martin R, Beck M, Eng C et al (2008) Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121:e377–e386
Miech C, Dierks T, Selmer T, von Figura K, Schmidt B (1998) Arylsulfatase from Klebsiella pneumoniae carries a formylglycine generated from a serine. J Biol Chem 273:4835–4837
Millat G, Froissart R, Maire I, Bozon D (1997) Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue. Biochem J 326(Pt 1):243–247
Nelson J (1997) Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet 101:355–358
Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR (ed) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, NY
Ochiai T, Suzuki Y, Kato T et al (2007) Natural history of extensive Mongolian spots in mucopolysaccharidosis type II (Hunter syndrome): a survey among 52 Japanese patients. J Eur Acad Dermatol Venereol 21:1082–1085
Parkinson EJ, Muller V, Hopwood JJ, Brooks DA (2004) Iduronate-2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients. Mol Genet Metab 81:58–64
Poorthuis BJ, Wevers RA, Kleijer WJ et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151–156
Rathmann M, Bunge S, Steglich C, Schwinger E, Gal A (1995) Evidence for an iduronate-sulfatase pseudogene near the functional Hunter syndrome gene in Xq27.3-q28. Hum Genet 95:34–38
Rathmann M, Bunge S, Beck M, Kresse H, Tylki-Szymanska A, Gal A (1996) Mucopolysaccharidosis type II (Hunter syndrome): mutation “hot spots” in the iduronate-2-sulfatase gene. Am J Hum Genet 59:1202–1209
Scarpa M, Almassy Z, Beck M et al (2011) Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 6:72
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57
Schwartz IV, Ribeiro MG, Mota JG et al (2007) A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl 96:63–70
Sohn YB, Ki CS, Kim CH et al (2012) Identification of 11 novel mutations in 49 Korean patients with mucopolysaccharidosis type II. Clin Genet 81:185–190
Steen-Bondeson ML, Dahl N, Tonnesen T et al (1992) Molecular analysis of patients with Hunter syndrome: implication of a region prone to structural alterations within the IDS gene. Hum Mol Genet 1:195–198
Sukegawa-Hayasaka K, Kato Z, Nakamura H et al (2006) Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis. J Inherit Metab Dis 29:755–761
Vafiadaki E, Cooper A, Heptinstall LE, Hatton CE, Thornley M, Wraith JE (1998) Mutation analysis in 57 unrelated patients with MPS II (Hunter’s disease). Arch Dis Child 79:237–241
Villani GR, Daniele A, Balzano N, Di Natale P (2000) Expression of five iduronate-2-sulfatase site-directed mutations. Biochim Biophys Acta 1501(2–3):71–80
Waldow A, Schmidt B, Dierks T, von Bulow R, von Figura K (1999) Amino acid residues forming the active site of arylsulfatase A. Role in catalytic activity and substrate binding. J Biol Chem 274:12284–12288
Whitley CB, Anderson RA, Aronovich EL et al (1993) Caveat to genotype-phenotype correlation in mucopolysaccharidosis type II: discordant clinical severity of R468W and R468Q mutations of the iduronate-2-sulfatase gene. Hum Mutat 2(3):235–23
Wilson PJ, Morris CP, Anson DS et al (1990) Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc Natl Acad Sci U S A 87:8531–8535
Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J (2008a) Initial report from the hunter outcome survey. Genet Med 10:508–516
Wraith JE, Scarpa M, Bec M et al (2008b) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277
Yatziv S, Erickson RP, Epstein CJ (1977) Mild and severe Hunter syndrome (MPS II) within the same sibships. Clin Genet 11:319–326
Young ID, Harper PS, Newcombe RG, Archer IM (1982) A clinical and genetic study of Hunter’s syndrome. 2. Differences between the mild and severe forms. J Med Genet 19:408–411
Zhang H, Li J, Zhang X et al (2011) Analysis of the IDS gene in 38 patients with Hunter syndrome: the c.879G > A (p.Gln293Gln) synonymous variation in a female create exonic splicing. PLoS One 6:e22951
Acknowledgments
To patients and their families, MRC-Holland for the donation of the MLPA kit for this research, ACOPEL, and Doctors Gabriel Sierra, Luz Norella Correa, Gustavo Contreras, Sandra Mansilla, and Juan Carlos Prieto. To professors Mauricio Rey, Rita Baldrich, Blanca Schroeder, Henry J Rodríguez, and other members of immunogenetics/biology group at Universidad Nacional de Colombia for their support relating to laboratory work. To Tatiana Vinasco, David Serrano, and Andres Gutierrez for contribution of literature and counseling.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Maurizio Scarpa, M.D, Ph.D
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Appendices
One-Sentence Take-Home Message
Deep genotyping and bioinformatic approaches can lead to a better understanding of Hunter syndrome (MPSII).
Compliance with Ethics Guidelines
All procedures followed were in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent for study participation was obtained from all patients included in the study.
This study included 18 Colombian patients with a diagnosis of MPS II whose familial or legal guardians gave informed consent. The informed consent was previously evaluated and approved by the Ethics Committee of the School of Medicine of the National University of Colombia (Comité de Etica de la Facultad de Medicina de la Universidad Nacional de Colombia). By Act Number 16 of November 5, 2010, the Ethics Committee approved the study. After a careful review, the Committee determined that the project meets the ethical requirements and complies with Approbatory Concept. Signed: Prof. CARLOS ARTURO GUERRERO, President of the Ethics Committee.
Conflict of Interest
Johanna Galvis, Jannet González, Alfredo Uribe declare that they have no conflict of interest. Harvy Velasco declares that he received an educative grant from Shire.
Details of the Contribution of Individual Authors
Johanna Galvis: Planning of the work; patients’ recruitment; clinical data extraction and analysis; genotyping steps at laboratory; bioinformatic simulations; reporting of the results; writing and revision of manuscript. Guarantor 1
Jannet Gonzalez: Bioinformatic simulations. Revision of bioinformatic results
Alfredo Uribe: IDS Enzyme assays results, additional clinical data of patients
Harvy Velasco: Planning of the work; patients’ recruitment; clinical data extraction and analysis. Revision of manuscript. Guarantor 2
Rights and permissions
Copyright information
© 2014 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Galvis, J., González, J., Uribe, A., Velasco, H. (2014). Deep Genotyping of the IDS Gene in Colombian Patients with Hunter Syndrome. In: Zschocke, J., Baumgartner, M., Morava, E., Patterson, M., Rahman, S., Peters, V. (eds) JIMD Reports, Volume 19. JIMD Reports, vol 19. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2014_376
Download citation
DOI: https://doi.org/10.1007/8904_2014_376
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46189-1
Online ISBN: 978-3-662-46190-7
eBook Packages: MedicineMedicine (R0)